Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Phenylketonuria (PKU) Treatment Market

Phenylketonuria (PKU) Treatment Market Trends

Report ID: GMI11037
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Phenylketonuria Treatment Market Trends

The growing prevalence of PKU is significantly driving the expansion of the PKU treatment market. As more cases are diagnosed, there is an increased demand for effective treatment solutions to manage this metabolic disorder.

For instance, according to the National Institutes of Health (NIH) in 2023, approximately 1 in 10,000 to 15,000 newborns worldwide are diagnosed with PKU, highlighting a substantial global incidence rate. This increasing prevalence underscored the critical need for effective treatment solutions and comprehensive management strategies for PKU patients thereby expanding the market adoption.
Thus, as more cases are identified due to enhanced newborn screening and greater awareness, there is an increasing need for effective management solutions. This rise in prevalence necessitated a demand for effective treatment options, including new drugs and advanced therapies, to address the growing patient population further drives the market demand.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The phenylketonuria treatment industry was valued at USD 737.7 million in 2023 and is anticipated to register a 7.2% CAGR between 2024 and 2032 augmented by the rising incidence of PKU globally and advancements in treatment options.

The classic PKU segment will showcase a 7% CAGR over 2024-2032, because of its high prevalence and the well-established need for lifelong management.

The U.S. PKU treatment market size is anticipated to reach USD 502.5 million by 2032, thrusted by advancements in diagnostic and treatment technologies.

Abbott Laboratories, American Gene Technologies, APR Applied Pharma Research s.a., BioMarin Pharmaceutical Inc., and Codexis, Inc., among others.